Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
1,5 About the Trial Trial Name: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW) ClinicalTrials.gov ID: NCT03819153 Sponsor: Novo Nordisk A/S Completion Date: January 9, 2024 In the trial, which enrolled a total of 3533 patients with T2D or CKD, once weekly semaglutide 1 mg led to a 24% reduction in the risk of kidney disease progression and kidney and cardiovascular mortality compared with placebo (331 vs 410 events
The trial enrolled more than 3,100 adults with obesity or overweight and at least one weight-related medical condition, excluding diabetes
Sau 4 tun da ca mnh ci thin v trng sng kh r, chc phi ln c t nht mt tng cc ch em , my vt thm mn cng m i hn, da ca mnh khng b nm nn khng r hiu qu gim nm c tt hay khng
Solutions: We began by conducting a comprehensive market and platform analysis to understand existing gaps and opportunities
Pregnant, breastfeeding, or pediatric patients Human data on multi-enzyme OTC supplements in pregnancy, breastfeeding, and young children are limited
Semaglutide is a GLP-1 receptor agonist, primarily used to treat type 2 diabetes and obesity
